SCHEMBL15469394

SCHEMBL15469394

Cc1ccc([C@@]2(NC(=O)c3ccncn3)CCOc3cccnc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.46
P2RX7 Q99572 1/20 0.36
CTNNB1 P35222 1/20 0.35
WNT3A P56704 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.34
GSK3A P49840 2/20 0.33
GSK3B P49841 2/20 0.33
XIAP P98170 1/20 0.33
BIRC2 Q13490 1/20 0.33
RAB9A P51151 4/20 0.32
NPC1 O15118 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
GRM4 Q14833 2/20 0.32
PKM P14618 1/20 0.32
TNKS O95271 1/20 0.32
FPR2 P25090 1/20 0.31
GRM5 P41594 1/20 0.31
PTGS2 P35354 1/20 0.31
FNTA P49354 1/20 0.31
FNTB P49356 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467624 0.89 TRPM8 (0.49) TRPM8P2RX7
SCHEMBL15467626 0.89 TRPM8 (0.49) TRPM8P2RX7
SCHEMBL15469407 0.87 TRPM8 (0.52) TRPM8RAB9ANPC1SMN1; SMN2FPR2
SCHEMBL15469401 0.85 TRPM8 (0.46) TRPM8P2RX7RAB9ANPC1SMN1; SMN2
SCHEMBL16418803 0.84 TRPM8 (0.46) TRPM8RAB9ANPC1SMN1; SMN2PKM
SCHEMBL15469549 0.83 TRPM8 (0.48) TRPM8RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL15467345 0.83 TRPM8 (0.53) TRPM8RAB9ANPC1SMN1; SMN2PTGS2
SCHEMBL15467342 0.83 TRPM8 (0.53) TRPM8RAB9ANPC1SMN1; SMN2PTGS2
SCHEMBL16418809 0.83 TRPM8 (0.46) TRPM8RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL16418808 0.83 TRPM8 (0.46) TRPM8IRAK4RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885P2RX7 178/4885CTNNB1 2569/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885P2RX7 178/4885CTNNB1 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.